Lipid 29 maintained consistent particle size and low PDI across 0-3 mol% PEG-lipid, including 0 mol%; long-term stability at very low PEG was not determined.
· Article section 2.3, Fig. 6.sales@dcchemicals.com
Moderna Lipid 29
Formulation & Performance
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| Lipid 29 | Not reported | Ionizable lipid |
| Structural phospholipid | Not reported | structural_lipid |
| Phospholipid (if used) | Not reported | Helper phospholipid |
| PEG-lipid | Not reported | PEG lipid |
| Reported total | Not reported | Source values retained |
Formulation calculator unavailable. The supplied article does not report the complete molar composition, so a formulation weight calculation is not available. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reportedHighest expression among tested series0.5 mg/kg IV bolus, CD-1 mice, n=5 · Lipid 1 and analog seriesArticle Fig. 1b and section 2.1
Literature-reported>20-fold versus lipid 1Whole-body bioluminescence · Lipid 1 LNPArticle Fig. S4 and section 2.1
Literature-reported2-fold higher0.1 mg/kg, 60-min IV infusion, n=6 · Lipid 1 LNPArticle Fig. 3
Literature-reported>6-fold higher0.1 mg/kg, 60-min IV infusion, n=6 · Lipid 1 LNPArticle Fig. 3
Reported in vivo performance
| Experiment | Condition | Lipid 29 result |
|---|---|---|
| Mouse hEPO mRNA | 0.5 mg/kg IV bolus, CD-1 mice, n=5 | Highest expression among the tested tail/headgroup series; lead selected |
| Mouse luciferase mRNA | Whole-body bioluminescence comparison | More than 20-fold greater AUEC than lipid 1 LNPs |
| Cynomolgus hEPO mRNA | 0.1 mg/kg, 60-min IV infusion, n=6 | Approximately 2-fold higher Emax and >6-fold higher AUEClast than lipid 1 |
| LNP structure | Cryo-EM/SAXS | Lipid 29 showed more organized multilamellar features; d-spacing 4.76 nm vs 6.56 nm for lipid 1 |
Additional reported findings
Molecular-dynamics simulations indicated squaramide 29 hydrogen-bond and pi-stacking interactions with exposed RNA nucleobases/sugars; this is a mechanistic hypothesis from simulations, not a standalone efficacy guarantee.
· Article section 2.2, Fig. 4.Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetCornebise M, et al. Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA. Advanced Functional Materials. 2022;32(8):2106727. DOI: 10.1002/adfm.202106727
All formulation and performance values are from Cornebise et al. and apply only to the cited cargo, composition, process, dose, model and comparator.
All formulation and performance values are from Cornebise et al. and apply only to the cited cargo, composition, process, dose, model and comparator.